Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kosmas C et al. – Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. TIP is an active regimen with acceptable toxicity in advanced/relapsed cervical cancer.

Exclusive Author Commentary
C Kosmas, 09/16/09

The Paclitaxel-Ifosfamide-Cisplatin (TIP) regimen appears to be active and relatively tolerable, except some slightly excessive (approx. 20%) rate of febrile neutropenic episodes, which are rapidly reversible mostly with home antibiotic therapy (amoxicillin/clavulanate+ciproxin). The regimen has shown to be highly active in patients with relapses outside previously irradiated pelvic sites, in particular lymph nodes and pulmonary metastases. Moreover, about 15% of patients with para-aortic lymph node metastases have experienced >2-year survival.

Related Articles

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study : The Lancet Oncology
The Lancet Oncology - Online First, 10/12/09    Relevance Score: 70%

Transvaginal doppler sonography for assessment the response to radiotherapy in locally advanced squamous cervical cancer: a preliminary study
Archives of Medical Science, 11/03/09    Relevance Score: 69%

Effectiveness of cervical cancer screening at different ages
Women's Health, 10/30/09    Relevance Score: 69%

A survey of the knowledge and attitude of Jordanian obstetricians and gynaecologists to cervical cancer screening
Journal of Obstetrics and Gynaecology, 10/29/09    Relevance Score: 69%

Interleukin-12 gene polymorphism and cervical cancer risk
American Journal of Clinical Oncology, 10/06/09    Relevance Score: 69%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address